Tranquillisation or asleep ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Specific behaviour ‐ agitation · psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome compared with COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE (very low certainty).
1 finding from 1 review
Adverse effects · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects compared with COMBINATIONS: f. OLANZAPINE + MAGNESIUM VALPROATE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquilisation or asleep · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquilisation or asleep compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for tranquillisation compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ threat or injury to self or others compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ need for benzodiazepine during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep: tranquillised/asleep ‐ by around 30 minutes · acute psychosis
Droperidol showed no clear difference in tranquillisation or asleep: tranquillised/asleep ‐ by around 30… compared with olanzapine (high certainty).
1 finding from 1 review
Global state: use of additional medication ‐ by 60 minutes after initial adequate sedation until ED discharge (various psychotropic drugs) · acute psychosis
Droperidol leads to lower global state: use of additional medication ‐ by 60 minutes after… compared with olanzapine (high certainty).
1 finding from 1 review
Adverse effects ‐ cardiovascular ‐ arrhythmia · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ cardiovascular ‐ arrhythmia compared with olanzapine (moderate certainty).
1 finding from 1 review
Adverse effects ‐ respiratory ‐ airway obstruction · acute psychosis
Droperidol showed no clear difference in adverse effects ‐ respiratory ‐ airway obstruction compared with olanzapine (low certainty).
1 finding from 1 review
Service use: person able to be discharged home · acute psychosis
Droperidol showed no clear difference in service use: person able to be discharged home compared with olanzapine (high certainty).
1 finding from 1 review
Mental state ‐ improvement · acute psychosis
1 finding from 1 review
Economic: direct costs · acute psychosis
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review